Mode
Text Size
Log in / Sign up
Phase 4 N=315 Randomized Treatment

PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)

Atrial Fibrillation

Enrolled (actual)
315
Serious AEs
4.1%
Results posted
Apr 2021
Primary outcome: Primary: Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications at Six Months After the Index Procedure — 99; 98 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
PV-Isolation RF (Procedure); PV-Isolation Cryo (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Staedtisches Klinikum Karlsruhe
Primary completion
Dec 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications at Six Months After the Index Procedure
99; 98
PRIMARY
Combined Endpoint Out of: Absence of Atrial Arrhythmias and Absence of Persistent Complications Twelve Months After Procedure.
103; 105
SECONDARY
Long-term Clinical Success
141; 141
SECONDARY
Total Radiation Exposure
50.0; 61.5
SECONDARY
Total Procedure Duration
162.0; 151.0
SECONDARY
Major Adverse Events
147; 144; 12; 12
SECONDARY
Mid-term Clinical Success
154; 150

Summary

This study is designed as a randomized, controlled, prospective, non-inferiority clinical trial, where the efficacy and safety of the cryoballoon ablation system (CE certificated) will be compared to the standard ablation technique (segmental isolation of the pulmonary veins) with radiofrequency energy. The primary study aim is to investigate whether the new cryoballoon ablation catheter system (Arctic Front CryoAblation Catheters, FlexCath Steerable Sheath, CryoCath Technologies Inc., Montreal, Canada) is at least as effective as radiofrequency (RF) segmental isolation in electrically disconnecting the pulmonary veins (PV) for the treatment of paroxysmal atrial fibrillation (AF) with respect to the absence of atrial arrhythmias without persistent complications after six and twelve months. Furthermore, the differences in terms of procedural complications such as pulmonary vein stenosis, phrenic nerve injuries, cerebrovascular accidents (CVA), pericardial tamponade, pain scores during the procedure, levels of cardiac inflammatory markers are compared between the treatment groups. The short and long-term clinical success as well as the costs of both systems will also be evaluated.

Eligibility Criteria

Inclusion Criteria

  • Documented paroxysmal PAF: PAF diagnosis, 2 episodes of PAF within the last 3 months, at least 1 episode of PAF must be documented.
  • Age 18-75
  • Documented effectiveness failure of at least 1 AAD including beta-blockers

Exclusion Criteria

  • AAD usage 55 mm
  • LA thrombus
  • Previous LA ablation/surgery, structural heart disease, heart failure class III-IV
  • Hypertrophic cardiomyopathy
  • Mitral prosthesis
  • Unstable angina
  • Uncontrolled hyperthyroidism
  • Stroke or TIA within 6 months
  • Myocardial infarction within 2 months
  • Cardiac surgery within 3 months
  • Thrombocytosis, thrombocytopenia
  • Any condition contraindicating chronic anticoagulation
  • EF < 40%
  • Pregnancy
  • Life expectancy < 1 year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00774566). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search